Stay updated on Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no changes to study content or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoChange DetectedThe notice about government funding and potential delays has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check31 days agoChange DetectedThe updates appear limited to formatting, dates, and minor UI sections; no changes to core study details or eligibility criteria are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check60 days agoChange DetectedUpgrade to v3.2.0 with an inserted government operating status notice; previous version v3.1.0 removed.SummaryDifference4%

- Check67 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

- Check74 days agoChange DetectedNew sponsor and study details added (Vanda Pharmaceuticals; a single-arm, multiple-dose study of imsidolimab for GPP with a detailed description and date references). The old sponsor/links from AnaptysBio, Inc. were removed.SummaryDifference5%

Stay in the know with updates to Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.